Bellevue Group AG Buys Sarepta Therapeutics Inc, Revolution Medicines Inc, Fate Therapeutics Inc, Sells Moderna Inc, Halozyme Therapeutics Inc, Charles River Laboratories International Inc

• New Purchases: SRPT, SGHT, PRCT, HRMY, PFE, NVAX, BCYC, DGX, ARCT, NTLA, CVAC, KYMR, ACIU,
• Added Positions: RVMD, FATE, SAGE, AMED, RLAY, JAZZ, BSX, TMO, MGNX, VCRA, SYK, EPIX, OPCH, PODD, EXAS, AXSM, ADPT, MRSN, HUM, INSP, DXCM, MYOV, NKTR, MTEM, INSM, ACCD, ITCI, PEN, VRTX, CTLT, HCM, SGEN, NVRO, ARGX, ATRC, IQV, RDUS, ANTM, GILD, TNDM, HCA, MRTX, LH, BAX, RARE, VEEV, RCUS, BMRN, CCCC, ZLAB,
• Reduced Positions: MRNA, HALO, CRL, GKOS, HRC, BIO, SILK, AMGN, ALNY, IONS, BGNE, CNC, EVH, NEO, CDNA, SWAV, BMY, CI, MOH, AXNX, TDOC, DHR, TMDX, ABBV, GH, LEGN, HOLX, QTRX, MDT, BNTX, IMAB, BHVN, EW, INGN, ILMN, UNH, EXEL, SYNH, BDX, HCAT, TFX, JNJ, CLLS, XNCR, OPT, SNY, OSCR,
• Sold Out: EAR, XENT, SGFY, ALXN, ACAD, DRNA, RXRX,

For the details of Bellevue Group AG's stock buys and sells, go to https://www.gurufocus.com/guru/bellevue+group+ag/current-portfolio/portfolio

1. Moderna Inc (MRNA) - 1,727,349 shares, 6.75% of the total portfolio. Shares reduced by 32.06%
2. Vertex Pharmaceuticals Inc (VRTX) - 1,761,616 shares, 3.24% of the total portfolio. Shares added by 1.61%
3. Ionis Pharmaceuticals Inc (IONS) - 9,347,926 shares, 3.18% of the total portfolio. Shares reduced by 5.86%
4. argenx SE (ARGX) - 983,938 shares, 3.02% of the total portfolio. Shares added by 1.02%
5. Neurocrine Biosciences Inc (NBIX) - 3,004,051 shares, 2.92% of the total portfolio. Shares reduced by 0.45%

Bellevue Group AG initiated holding in Sarepta Therapeutics Inc. The purchase prices were between $65.97 and $92.48, with an estimated average price of $77.05. The stock is now traded at around $85.995000. The impact to a portfolio due to this purchase was 0.53%. The holding were 569,168 shares as of 2021-09-30.

Bellevue Group AG initiated holding in Sight Sciences Inc. The purchase prices were between $22.34 and $39.1, with an estimated average price of $32.86. The stock is now traded at around $24.130600. The impact to a portfolio due to this purchase was 0.07%. The holding were 300,000 shares as of 2021-09-30.

Bellevue Group AG initiated holding in PROCEPT BioRobotics Corp. The purchase prices were between $35.91 and $41.94, with an estimated average price of $38.38. The stock is now traded at around $40.900000. The impact to a portfolio due to this purchase was 0.06%. The holding were 150,000 shares as of 2021-09-30.

Bellevue Group AG initiated holding in Harmony Biosciences Holdings Inc. The purchase prices were between $25.68 and $38.61, with an estimated average price of $32.22. The stock is now traded at around $43.015000. The impact to a portfolio due to this purchase was 0.05%. The holding were 129,289 shares as of 2021-09-30.

Bellevue Group AG initiated holding in Pfizer Inc. The purchase prices were between $39.25 and $50.42, with an estimated average price of $44.27. The stock is now traded at around $49.675500. The impact to a portfolio due to this purchase was 0.04%. The holding were 99,600 shares as of 2021-09-30.

Bellevue Group AG initiated holding in Bicycle Therapeutics PLC. The purchase prices were between $27.95 and $44.24, with an estimated average price of $35.01. The stock is now traded at around $57.330000. The impact to a portfolio due to this purchase was 0.03%. The holding were 65,700 shares as of 2021-09-30.

Bellevue Group AG added to a holding in Revolution Medicines Inc by 86.48%. The purchase prices were between $23.95 and $33.41, with an estimated average price of $29.16. The stock is now traded at around $32.465000. The impact to a portfolio due to this purchase was 0.45%. The holding were 3,458,805 shares as of 2021-09-30.

Bellevue Group AG added to a holding in Sage Therapeutics Inc by 35.73%. The purchase prices were between $40.26 and $57.37, with an estimated average price of $46.02. The stock is now traded at around $42.150000. The impact to a portfolio due to this purchase was 0.38%. The holding were 3,209,004 shares as of 2021-09-30.

Bellevue Group AG added to a holding in Fate Therapeutics Inc by 23.89%. The purchase prices were between $59.27 and $95.73, with an estimated average price of $78.58. The stock is now traded at around $55.810000. The impact to a portfolio due to this purchase was 0.38%. The holding were 3,238,036 shares as of 2021-09-30.

Bellevue Group AG added to a holding in Amedisys Inc by 400.60%. The purchase prices were between $149.1 and $270.32, with an estimated average price of $208.37. The stock is now traded at around $181.990000. The impact to a portfolio due to this purchase was 0.37%. The holding were 302,798 shares as of 2021-09-30.

Bellevue Group AG added to a holding in Relay Therapeutics Inc by 42.22%. The purchase prices were between $29.75 and $37.99, with an estimated average price of $33.69. The stock is now traded at around $35.470000. The impact to a portfolio due to this purchase was 0.36%. The holding were 3,755,962 shares as of 2021-09-30.

Bellevue Group AG added to a holding in Jazz Pharmaceuticals PLC by 41.21%. The purchase prices were between $128.64 and $184.79, with an estimated average price of $151.34. The stock is now traded at around $136.595000. The impact to a portfolio due to this purchase was 0.3%. The holding were 769,238 shares as of 2021-09-30.

Bellevue Group AG sold out a holding in Eargo Inc. The sale prices were between $6.59 and $38.71, with an estimated average price of $26.78.

Bellevue Group AG sold out a holding in Intersect ENT Inc. The sale prices were between $18.11 and $28.01, with an estimated average price of $24.68.

Bellevue Group AG sold out a holding in Signify Health Inc. The sale prices were between $17.87 and $30.5, with an estimated average price of $25.79.

Bellevue Group AG sold out a holding in . The sale prices were between $179.45 and $186.61, with an estimated average price of $183.84.

Bellevue Group AG sold out a holding in Dicerna Pharmaceuticals Inc. The sale prices were between $19.68 and $39.99, with an estimated average price of $27.67.

Bellevue Group AG sold out a holding in ACADIA Pharmaceuticals Inc. The sale prices were between $15.78 and $24.77, with an estimated average price of $19.31.